ライフサイエンスコーパス: atherosclerotic cardiovascular disease

1 so associated with a doubling of the risk of atherosclerotic cardiovascular disease.

2 th type 2 diabetes mellitus and a history of atherosclerotic cardiovascular disease.

3 a similar benefit in those with and without atherosclerotic cardiovascular disease.

4 he current approach to primary prevention of atherosclerotic cardiovascular disease.

5 f alcohol might mitigate some of the risk of atherosclerotic cardiovascular disease.

6 both the primary and secondary prevention of atherosclerotic cardiovascular disease.

7 ergence in development and HPSC expansion in atherosclerotic cardiovascular disease.

8 3 participants were admitted to hospital for atherosclerotic cardiovascular disease.

9 ovascular death in patients with established atherosclerotic cardiovascular disease.

10 associated with incident type 2 diabetes and atherosclerotic cardiovascular disease.

11 poiesis correlates with an increased risk of atherosclerotic cardiovascular disease.

12 sterol is a well established risk factor for atherosclerotic cardiovascular disease.

13 ntative US adult population with established atherosclerotic cardiovascular disease.

14 nd expenditures among those with established atherosclerotic cardiovascular disease.

15 ients with type 2 diabetes mellitus who have atherosclerotic cardiovascular disease.

16 s are effective in the primary prevention of atherosclerotic cardiovascular disease.

17 the aging process and may play a key role in atherosclerotic cardiovascular disease.

18 oprotein cholesterol (LDL-C) and accelerated atherosclerotic cardiovascular disease.

19 ow-density lipoprotein will decrease risk of atherosclerotic cardiovascular disease.

20 eved glycemic targets and who have prevalent atherosclerotic cardiovascular disease.

21 (LDL-C) and extremely high risk of premature atherosclerotic cardiovascular disease.

22 lower LDL cholesterol, a causative agent for atherosclerotic cardiovascular disease.

23 as the most effective way to reduce risk of atherosclerotic cardiovascular disease.

24 fication of new, modifiable risk factors for atherosclerotic cardiovascular disease.

25 important contributor to the pathobiology of atherosclerotic cardiovascular disease.

26 and personal and family history of premature atherosclerotic cardiovascular disease.

27 have an inverse relationship to the risk of atherosclerotic cardiovascular disease.

28 the morbidity and mortality associated with atherosclerotic cardiovascular disease.

29 of the 1p13 SORT1 locus for the treatment of atherosclerotic cardiovascular disease.

30 new therapeutic targets for the treatment of atherosclerotic cardiovascular disease.

31 l mediators that link diabetes mellitus with atherosclerotic cardiovascular disease.

32 y lipoprotein lowering and for prevention of atherosclerotic cardiovascular disease.

33 holesterol is an independent risk factor for atherosclerotic cardiovascular disease.

34 to assess an individual's risk of developing atherosclerotic cardiovascular disease.

35 (HDL-C) are associated with protection from atherosclerotic cardiovascular disease.

36 ion between chronic bacterial infections and atherosclerotic cardiovascular disease.

37 of aging: shingles, Alzheimer's disease and atherosclerotic cardiovascular disease.

38 ated in promoting the metabolic syndrome and atherosclerotic cardiovascular disease.

39 its potential as a therapeutic approach for atherosclerotic cardiovascular disease.

40 therapeutic targeting of SMC transitions in atherosclerotic cardiovascular disease.

41 and advancing age is a major risk factor for atherosclerotic cardiovascular disease.

42 olesterol and an increased risk of premature atherosclerotic cardiovascular disease.

43 atopoiesis associates with increased risk of atherosclerotic cardiovascular disease.

44 l of 'Trojan horse' nanoparticles to prevent atherosclerotic cardiovascular disease.

45 ed with hypolipidemia and protection against atherosclerotic cardiovascular disease.

46 vonoid intake and hospital admissions due to atherosclerotic cardiovascular disease.

47 outcomes mainly in patients with established atherosclerotic cardiovascular disease.

48 diabetes and risk factors for or established atherosclerotic cardiovascular disease.

49 t seem confined to patients with established atherosclerotic cardiovascular disease.

50 e strongly associated with long-term risk of atherosclerotic cardiovascular disease.

51 the polypill among patients with established atherosclerotic cardiovascular disease.

52 nce indicates an association between HCV and atherosclerotic cardiovascular disease.

53 n obesity and are positively correlated with atherosclerotic cardiovascular diseases.

54 14), with benefit only seen in patients with atherosclerotic cardiovascular disease (0.86 [0.80-0.93]

55 0.672 for ADA HbA1c clinical categories for atherosclerotic cardiovascular disease, 0.701 for ADA fa

56 culating cystathionine levels are related to atherosclerotic cardiovascular disease, a leading cause

57 has been associated with a greater risk for atherosclerotic cardiovascular disease (ACD).

58 on study on stools from 218 individuals with atherosclerotic cardiovascular disease (ACVD) and 187 he

59 tion between periodontitis (PD) and incident atherosclerotic cardiovascular disease (ACVD), including

60 th the association between periodontitis and atherosclerotic cardiovascular disease (ACVD).

61 ong adults aged 30-84 years with established atherosclerotic cardiovascular disease, adoption of the

62 Association endorses statins for adults with atherosclerotic cardiovascular disease, adults with LDL

63 modest health benefits, reducing DALYs from atherosclerotic cardiovascular disease among patients wi

64 ed with lower risk of heart failure (HF) and atherosclerotic cardiovascular disease among patients wi

65 data for eGFR); 6974 (40.6%) had established atherosclerotic cardiovascular disease and 10 186 (59.4%

66 volocumab vs placebo in patients with stable atherosclerotic cardiovascular disease and a baseline LD

67 iation study on stools from individuals with atherosclerotic cardiovascular disease and healthy contr

68 Dyslipidemia increases the risk of atherosclerotic cardiovascular disease and is incomplete

69 Furthermore, as this population ages, atherosclerotic cardiovascular disease and its risk fact

70 trolled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholester

71 ebo-controlled trial involving patients with atherosclerotic cardiovascular disease and low-density l

72 2 diabetes both with and without established atherosclerotic cardiovascular disease and mostly with p

73 blish essential roles for Tregs in resolving atherosclerotic cardiovascular disease and provide mecha

74 wering strategies in high-risk patients with atherosclerotic cardiovascular disease and supports the

75 similar benefit in patients with and without atherosclerotic cardiovascular disease and with and with

76 ith type 2 diabetes mellitus and concomitant atherosclerotic cardiovascular disease and/or kidney dis

77 ith type 2 diabetes mellitus and concomitant atherosclerotic cardiovascular disease and/or kidney dis

78 rticipants with type 2 diabetes mellitus and atherosclerotic cardiovascular disease and/or kidney dis

79 ure (HF), particularly those with coexisting atherosclerotic cardiovascular disease and/or kidney dis

80 aged 50-65 years, had no previous history of atherosclerotic cardiovascular disease, and had complete

81 of the consistent data for benefit for both atherosclerotic cardiovascular disease- and HF-related o

82 (LDL-C) >/=190 mg/dL are at a higher risk of atherosclerotic cardiovascular disease as a result of lo

83 Atherosclerotic cardiovascular disease (ASCVD) affects m

84 iency virus (PLHIV) are at increased risk of atherosclerotic cardiovascular disease (ASCVD) and are p

85 and joint associations of Lp(a) and FHx with atherosclerotic cardiovascular disease (ASCVD) and CHD a

86 zygous familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD) and have

87 statin treatment for secondary prevention of atherosclerotic cardiovascular disease (ASCVD) and proba

88 determine estimated 10-year absolute risk of atherosclerotic cardiovascular disease (ASCVD) and to de

89 ups of patients have enhanced propensity for atherosclerotic cardiovascular disease (ASCVD) associate

90 oward reduction in 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD) by implem

91 fatal or non-fatal stroke) using the revised Atherosclerotic Cardiovascular Disease (ASCVD) calculato

92 Atherosclerotic cardiovascular disease (ASCVD) continues

93 gh risk (VHR) based on a history of >1 major atherosclerotic cardiovascular disease (ASCVD) event or

94 a paradigm shift in strategies for reducing atherosclerotic cardiovascular disease (ASCVD) events by

95 is vital in therapy for patients at risk for atherosclerotic cardiovascular disease (ASCVD) events gi

96 on (ACC/AHA) Pooled Cohort Risk Equation for atherosclerotic cardiovascular disease (ASCVD) events in

97 oronary artery calcium (CAC) score, incident atherosclerotic cardiovascular disease (ASCVD) events, a

98 Atherosclerotic cardiovascular disease (ASCVD) events, i

99 Coronary artery calcium (CAC) predicts atherosclerotic cardiovascular disease (ASCVD) events, i

100 ng therapy in patients at very high risk for atherosclerotic cardiovascular disease (ASCVD) events.

101 (PAD) is associated with increased risk for atherosclerotic cardiovascular disease (ASCVD) events.

102 statin lipid-modifying medications to reduce atherosclerotic cardiovascular disease (ASCVD) events.

103 ing statin therapy for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in adults

104 Although risk factors for atherosclerotic cardiovascular disease (ASCVD) in famili

105 ations to estimate 10-year absolute risk for atherosclerotic cardiovascular disease (ASCVD) in primar

106 Atherosclerotic cardiovascular disease (ASCVD) is associ

107 Accurate risk assessment of atherosclerotic cardiovascular disease (ASCVD) is essent

108 Atherosclerotic cardiovascular disease (ASCVD) is the le

109 in 200 individuals in the United States, but atherosclerotic cardiovascular disease (ASCVD) outcomes

110 therapy for adults with an estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk >/=7

111 Besides age, other discriminators of atherosclerotic cardiovascular disease (ASCVD) risk are

112 women 45 to 84 years of age without clinical atherosclerotic cardiovascular disease (ASCVD) risk at e

113 ults 40 to 70 years of age who are at higher atherosclerotic cardiovascular disease (ASCVD) risk but

114 rt Association cholesterol guidelines to the atherosclerotic cardiovascular disease (ASCVD) risk esti

115 the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease (ASCVD) risk in a

116 Estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk in d

117 on cognition, we examined the ability of the Atherosclerotic Cardiovascular Disease (ASCVD) risk scor

118 The use of atherosclerotic cardiovascular disease (ASCVD) risk to p

119 individuals with a higher 10-year predicted atherosclerotic cardiovascular disease (ASCVD) risk, cal

120 L)-cholesterol lowering in the management of atherosclerotic cardiovascular disease (ASCVD) risk.

121 heterogeneity among individuals for CHD and atherosclerotic cardiovascular disease (ASCVD) risk.

122 reatment with statins to a 7.5% 10-year hard atherosclerotic cardiovascular disease (ASCVD) risk.

123 g from beliefs that these lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) to being

124 tions for treating adults without history of atherosclerotic cardiovascular disease (ASCVD) with stat

125 recommend initiating primary prevention for atherosclerotic cardiovascular disease (ASCVD) with stat

126 ociated with worse outcomes in patients with atherosclerotic cardiovascular disease (ASCVD), a group

127 In patients with atherosclerotic cardiovascular disease (ASCVD), guidelin

128 Risk of incident atherosclerotic cardiovascular disease (ASCVD), heart fa

129 between neighborhood disadvantage and major atherosclerotic cardiovascular disease (ASCVD)-related e

130 d systemic lupus erythematosus predispose to atherosclerotic cardiovascular disease (ASCVD).

131 V infection is associated with mortality and atherosclerotic cardiovascular disease (ASCVD).

132 k assessment report on primary prevention of atherosclerotic cardiovascular disease (ASCVD).

133 ears to identify those at increased risk for atherosclerotic cardiovascular disease (ASCVD).

134 an individuals with subclinical and clinical atherosclerotic cardiovascular disease (ASCVD).

135 Approximately 97% of patients had atherosclerotic cardiovascular disease (ASCVD).

136 mainstay in the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD).

137 recommended for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD).

138 length (TL) in leukocytes is associated with atherosclerotic cardiovascular disease (ASCVD).

139 or individuals with >/=7.5% 10-year risk for atherosclerotic cardiovascular disease (ASCVD).

140 s of zero are associated with a low risk for atherosclerotic cardiovascular disease (ASCVD).

141 n genetic disorder associated with premature atherosclerotic cardiovascular disease (ASCVD).

142 comprehensively in the prevention of primary atherosclerotic cardiovascular disease (ASCVD).

143 rt pathway, is independently associated with atherosclerotic cardiovascular disease (ASCVD).

144 sclerosis enrolled 6814 adults without known atherosclerotic cardiovascular disease (ASCVD).

145 deficiency virus (PWH) demonstrate increased atherosclerotic cardiovascular disease (ASCVD).

146 vel therapeutic opportunity for treatment of atherosclerotic cardiovascular disease (ASCVD).

147 erol (LDL-C) and increased risk of premature atherosclerotic cardiovascular disease (ASCVD).

148 taking statins for the primary prevention of atherosclerotic cardiovascular disease (ASCVD).

149 nherited disorders associated with premature atherosclerotic cardiovascular disease (ASCVD).

150 ew paradigm linking aging, inflammation, and atherosclerotic cardiovascular disease (ASCVD).

151 For example, the new focus on total atherosclerotic cardiovascular diseases (ASCVD) is now i

152 DL-C testing patterns by patient risk group (atherosclerotic cardiovascular disease [ASCVD], diabetes

153 These findings show that patients with atherosclerotic cardiovascular disease benefit from lowe

154 048), including in patients with established atherosclerotic cardiovascular disease but no history of

155 reatment not only for patients with T2DM and atherosclerotic cardiovascular disease, but also in thos

156 otic management of patients with established atherosclerotic cardiovascular disease, but major guidel

157 ases, including type 2 diabetes mellitus and atherosclerotic cardiovascular disease, but remain to be

158 evidence for an association between CHIP and atherosclerotic cardiovascular disease, but the nature o

159 ) and the presence or absence of established atherosclerotic cardiovascular disease (cardiorenal outc

160 predictor of coronary heart disease and all atherosclerotic cardiovascular disease combined outcomes

161 and simvastatin for secondary prevention of atherosclerotic cardiovascular disease compared with cur

162 recently defined, clinical risk factors for atherosclerotic cardiovascular disease; consider current

163 ments in 2 subgroups of patients with stable atherosclerotic cardiovascular disease currently receivi

164 The lifetime risk of atherosclerotic cardiovascular disease (CVD) for persons

165 oprotein B (apoB) have been shown to predict atherosclerotic cardiovascular disease (CVD) in adults e

166 risk alleles significantly increase risk for atherosclerotic cardiovascular disease (CVD) in African

167 abetes mellitus (T1DM) increases the risk of atherosclerotic cardiovascular disease (CVD) in humans b

168 rt risk equations were developed to estimate atherosclerotic cardiovascular disease (CVD) risk and gu

169 Although HIV is associated with increased atherosclerotic cardiovascular disease (CVD) risk, it is

170 tin therapy to those at the highest absolute atherosclerotic cardiovascular disease (CVD) risk.

171 a role in the preclinical pathophysiology of atherosclerotic cardiovascular disease (CVD), an inflamm

172 d the most prevalent genetic risk marker for atherosclerotic cardiovascular disease (CVD), little pro

173 ellitus (T1DM and T2DM) increase the risk of atherosclerotic cardiovascular disease (CVD), resulting

174 and in patients with and without history of atherosclerotic cardiovascular disease (CVD).

175 heritable traits and major risk factors for atherosclerotic cardiovascular disease (CVD).

176 e 1 and type 2 diabetes increase the risk of atherosclerotic cardiovascular disease (CVD).

177 bstantially larger health gains (up to 24.3% atherosclerotic cardiovascular disease DALYs averted).

178 The primary end point was atherosclerotic cardiovascular disease, defined as a fir

179 4 large population studies without baseline atherosclerotic cardiovascular disease: DHS (Dallas Hear

180 Because clinical atherosclerotic cardiovascular disease does not manifest

181 Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin wa

182 th Pooled Cohort Equations-predicted 10-year atherosclerotic cardiovascular disease event risk <5% (o

183 ntal value to current practice guidelines in atherosclerotic cardiovascular disease event risk predic

184 Primary outcome was an atherosclerotic cardiovascular disease event, and second

185 Over a follow-up of 3 years, 19 atherosclerotic cardiovascular disease events (9 strokes

186 ndently associated with a 3-fold increase in atherosclerotic cardiovascular disease events among PLWH

187 s associated with a 3-fold increased risk of atherosclerotic cardiovascular disease events and a 4-fo

188 prevention and the effect of lipid drugs on atherosclerotic cardiovascular disease events and advers

189 K9 inhibitors demonstrate that reductions in atherosclerotic cardiovascular disease events are more e

190 The individual-level risk of atherosclerotic cardiovascular disease events in primary

191 total of 10 470 men and women without prior atherosclerotic cardiovascular disease events or heart f

192 dose of aspirin for secondary prevention of atherosclerotic cardiovascular disease events.

193 iation Pooled Cohort Equations in predicting atherosclerotic cardiovascular disease events.

194 ical data included baseline lipid levels and atherosclerotic cardiovascular disease events.

195 essive phenotypes with higher LDL-C and more atherosclerotic cardiovascular disease events.

196 ) are associated with lower lifetime risk of atherosclerotic cardiovascular disease) events.

197 standard background therapy in patients with atherosclerotic cardiovascular disease exceeds generally

198 nge of disorders, including type 2 diabetes, atherosclerotic cardiovascular disease, fatty liver dise

199 Current guidelines for atherosclerotic cardiovascular disease focus on high-int

200 We studied 14 298 patients with atherosclerotic cardiovascular disease from the FOURIER

201 and diabetes or a 10-year predicted risk for atherosclerotic cardiovascular disease >/=7.5% estimated

202 pective clinical trials in participants with atherosclerotic cardiovascular disease has provided guid

203 e prevalence of traditional risk factors for atherosclerotic cardiovascular diseases has been increas

204 The metabolic syndrome and atherosclerotic cardiovascular disease have long been li

205 abetes who have, or who are at high risk of, atherosclerotic cardiovascular disease have provided new

206 omes were stratified by baseline presence of atherosclerotic cardiovascular disease, heart failure, a

207 A total of 779 patients with atherosclerotic cardiovascular disease, heterozygous fam

208 ed, controlled trial involving patients with atherosclerotic cardiovascular disease, heterozygous fam

209 ry intake plays a role in the development of atherosclerotic cardiovascular disease; however, few stu

210 of all apoB-containing lipoproteins causing atherosclerotic cardiovascular disease; however, it is u

211 day was associated with a 14% lower risk of atherosclerotic cardiovascular disease (HR 0.86, 95% CI

212 Similarly, presence of atherosclerotic cardiovascular disease (HR, 0.83 [95% CI

213 ia, and a predisposition to type 2 diabetes, atherosclerotic cardiovascular disease, hypertension, an

214 Knowledge of the 10-year risk for atherosclerotic cardiovascular disease identifies patien

215 narios including estimating initial risk for atherosclerotic cardiovascular disease in a primary prev

216 as paradigms for the prevention of premature atherosclerotic cardiovascular disease in all at-risk pa

217 ith current care for secondary prevention of atherosclerotic cardiovascular disease in China, India,

218 Fewer than 25% of patients with atherosclerotic cardiovascular disease in countries of l

219 e available on their relation to subclinical atherosclerotic cardiovascular disease in humans.

220 which was shown to inversely correlate with atherosclerotic cardiovascular disease in populations wi

221 is crucial for the reduction in the risk of atherosclerotic cardiovascular disease in the population

222 serum low-density lipoprotein and, thereby, atherosclerotic cardiovascular diseases in obese humans.

223 n patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease, in comparison wi

224 th growing knowledge of the genetic basis of atherosclerotic cardiovascular disease-in particular, co

225 izing statin therapy, expanding the focus to atherosclerotic cardiovascular disease (including stroke

226 Atherosclerotic cardiovascular disease is a leading caus

227 An individual's susceptibility to atherosclerotic cardiovascular disease is influenced by

228 rongest association with LDL cholesterol and atherosclerotic cardiovascular disease is the 1p13 sorti

229 As atherosclerotic cardiovascular disease is the leading ca

230 ry disease (PAD), the third leading cause of atherosclerotic cardiovascular disease, is undetermined.

231 plorer database) and hospital admissions for atherosclerotic cardiovascular disease, ischaemic heart

232 single most important genetic risk factor), atherosclerotic cardiovascular disease, Lewy body dement

233 Beneficial effects of fish oil diets in atherosclerotic cardiovascular disease may involve impro

234 versus placebo in patients with established atherosclerotic cardiovascular disease (median follow-up

235 type 2 diabetes with and without established atherosclerotic cardiovascular disease, most of whom had

236 ardiovascular risk was defined as documented atherosclerotic cardiovascular disease, multiple cardiov

237 ellitus and either multiple risk factors for atherosclerotic cardiovascular disease (n=10 186) or kno

238 e 2 diabetes mellitus and either established atherosclerotic cardiovascular disease (n=6974) or multi

239 c cardiovascular disease (n=10 186) or known atherosclerotic cardiovascular disease (n=6974).

240 rcANRIL), which is transcribed at a locus of atherosclerotic cardiovascular disease on chromosome 9p2

241 sion of renal disease regardless of existing atherosclerotic cardiovascular disease or a history of h

242 r disease (ORION-10 trial) and patients with atherosclerotic cardiovascular disease or an atheroscler

243 nt with a strong family history of premature atherosclerotic cardiovascular disease or genetic dyslip

244 Cumulative incidence rates for CV event (atherosclerotic cardiovascular disease or heart failure)

245 7.5-113.1 mmol/mol), with either established atherosclerotic cardiovascular disease or multiple risk

246 ess of the patient's previous history of AF, atherosclerotic cardiovascular disease, or HF.

247 We enrolled patients with atherosclerotic cardiovascular disease (ORION-10 trial)

248 x capacity and its association with incident atherosclerotic cardiovascular disease outcomes in a lar

249 terol (HDL-C) level on the expected rates of atherosclerotic cardiovascular disease over the succeedi

250 included age >65 years (P<0.01), history of atherosclerotic cardiovascular disease (P<0.01), prescri

251 ank type 2 diabetes are at increased risk of atherosclerotic cardiovascular disease, partially due to

252 Atherosclerotic cardiovascular disease patients reportin

253 Despite all patients having atherosclerotic cardiovascular disease, patients in EMPA

254 Aspirin for primary atherosclerotic cardiovascular disease prevention as bas

255 ardiovascular events in patients with stable atherosclerotic cardiovascular disease regardless of whe

256 d-lowering recommendations for prevention of atherosclerotic cardiovascular disease rely principally

257 Atherosclerotic cardiovascular disease remains a major c

258 Atherosclerotic cardiovascular disease remains a major p

259 th familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease requiring additio

260 y of menopause before age 40 years to refine atherosclerotic cardiovascular disease risk assessments

261 cy (HDP) among women may be useful to refine atherosclerotic cardiovascular disease risk assessments.

262 symptomatic adults-even those with a 10-year atherosclerotic cardiovascular disease risk below 7.5%.

263 atherosclerotic cardiovascular disease or an atherosclerotic cardiovascular disease risk equivalent (

264 PDAY scores, reflecting increased aggregate atherosclerotic cardiovascular disease risk factor burde

265 The use of n-3 FA (4 g/d) for improving atherosclerotic cardiovascular disease risk in patients

266 Substantial reduction in expected atherosclerotic cardiovascular disease risk in the next

267 HDL-P for MI by Black ethnicity suggest that atherosclerotic cardiovascular disease risk may differ b

268 he clinician and patient about potential for atherosclerotic cardiovascular disease risk reduction be

269 cohort risk equations were used to estimate atherosclerotic cardiovascular disease risk score based

270 ompared to coronary artery calcium score and atherosclerotic cardiovascular disease risk score for MA

271 The median 10-year atherosclerotic cardiovascular disease risk score of the

272 Atherosclerotic cardiovascular disease risk score, coron

273 s, potential reductions in predicted 30-year atherosclerotic cardiovascular disease risk were greater

274 adolescents may be susceptible to aggregate atherosclerotic cardiovascular disease risk, as measured

275 rotein inhibitors have also failed to reduce atherosclerotic cardiovascular disease risk, despite pro

276 ment of LDL cholesterol for the reduction in atherosclerotic cardiovascular disease risk, which are i

277 ther refine the assessment and management of atherosclerotic cardiovascular disease risk.

278 s with or without metformin in those at high atherosclerotic cardiovascular disease risk.

279 senting 18.3 million adults with established atherosclerotic cardiovascular disease (self-reported or

280 rrent era, most patients without established atherosclerotic cardiovascular disease should not be pre

281 athophysiology among preeclampsia, IUGR, and atherosclerotic cardiovascular disease, statins have bee

282 uss the mechanisms underlying HIV-associated atherosclerotic cardiovascular disease, such as the high

283 guidelines incorporate a new risk score for atherosclerotic cardiovascular disease that includes str

284 ipoprotein C3 (APOC3) as a central player in atherosclerotic cardiovascular disease that is commonly

285 with moderate-high future risk of developing atherosclerotic cardiovascular disease, the efficacy and

286 th type 2 diabetes mellitus without clinical atherosclerotic cardiovascular disease to guide the use

287 y assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg o

288 e considered preoperatively in patients with atherosclerotic cardiovascular disease undergoing vascul

289 Risk for atherosclerotic cardiovascular disease was a novel consi

290 The primary composite endpoint of atherosclerotic cardiovascular disease was defined as th

291 ns of disturbed flow are the focal points of atherosclerotic cardiovascular disease, we hypothesized

292 registry of outpatients with or at risk for atherosclerotic cardiovascular disease-we compared the u

293 ment, patients who were older, male, and had atherosclerotic cardiovascular disease were more likely

294 effectiveness of evolocumab in patients with atherosclerotic cardiovascular disease when added to sta

295 e the inverse relationship between HDL-P and atherosclerotic cardiovascular disease, whereas adjustme

296 s to thromboembolic events in the setting of atherosclerotic cardiovascular disease, which is often p

297 se, using US clinical practice patients with atherosclerotic cardiovascular disease with low-density

298 and 34 322 patients (60.2% with established atherosclerotic cardiovascular disease), with 3342 major

299 y adults >=18 years of age with a history of atherosclerotic cardiovascular disease without safety co

300 currently prescribed any prevention drug for atherosclerotic cardiovascular disease would receive the